[HTML][HTML] Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6
MA Nauck, DR Quast - Frontiers in endocrinology, 2021 - frontiersin.org
To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
[HTML][HTML] Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
MA Nauck, DR Quast - Frontiers in Endocrinology, 2021 - ncbi.nlm.nih.gov
To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
MA Nauck, DR Quast - … Perspectives on Semaglutide: A GLP-1 …, 2021 - books.google.com
Independent of other conventional risk factors, diabetes confers an approximately two-fold
increased risk for cardiovascular (CV) disease (CVD) compared with individuals without …
increased risk for cardiovascular (CV) disease (CVD) compared with individuals without …
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
MA Nauck, DR Quast - Frontiers in Endocrinology, 2021 - cir.nii.ac.jp
抄録< jats: p> To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials
(CVOTs) have assessed the effects of new glucose-lowering therapies, including glucagon …
(CVOTs) have assessed the effects of new glucose-lowering therapies, including glucagon …
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
MA Nauck, DR Quast - Frontiers in endocrinology, 2021 - pubmed.ncbi.nlm.nih.gov
To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
MA Nauck, DR Quast - Frontiers in Endocrinology, 2021 - europepmc.org
To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …